X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs VENUS REMEDIES - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD VENUS REMEDIES MERCK LTD/
VENUS REMEDIES
 
P/E (TTM) x 47.0 -4.1 - View Chart
P/BV x 6.9 0.2 4,517.0% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 MERCK LTD   VENUS REMEDIES
EQUITY SHARE DATA
    MERCK LTD
Dec-17
VENUS REMEDIES
Mar-18
MERCK LTD/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,358126 1,078.2%   
Low Rs93361 1,527.0%   
Sales per share (Unadj.) Rs665.0301.8 220.4%  
Earnings per share (Unadj.) Rs56.6-24.9 -227.5%  
Cash flow per share (Unadj.) Rs72.52.5 2,848.3%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs441.7293.3 150.6%  
Shares outstanding (eoy) m16.6012.34 134.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.70.3 555.8%   
Avg P/E ratio x20.2-3.8 -538.5%  
P/CF ratio (eoy) x15.836.7 43.0%  
Price / Book Value ratio x2.60.3 813.3%  
Dividend payout %26.50-   
Avg Mkt Cap Rs m19,0111,154 1,647.7%   
No. of employees `0001.50.9 166.9%   
Total wages/salary Rs m1,696393 431.5%   
Avg. sales/employee Rs Th7,150.04,026.1 177.6%   
Avg. wages/employee Rs Th1,098.7425.0 258.5%   
Avg. net profit/employee Rs Th608.2-331.8 -183.3%   
INCOME DATA
Net Sales Rs m11,0403,724 296.4%  
Other income Rs m24023 1,065.3%   
Total revenues Rs m11,2793,747 301.1%   
Gross profit Rs m1,376395 348.6%  
Depreciation Rs m264338 78.0%   
Interest Rs m0354 0.0%   
Profit before tax Rs m1,352-275 -491.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m58332 1,844.3%   
Profit after tax Rs m939-307 -306.0%  
Gross profit margin %12.510.6 117.6%  
Effective tax rate %43.1-11.5 -375.6%   
Net profit margin %8.5-8.2 -103.2%  
BALANCE SHEET DATA
Current assets Rs m7,5232,638 285.2%   
Current liabilities Rs m2,2532,305 97.7%   
Net working cap to sales %47.78.9 533.9%  
Current ratio x3.31.1 291.8%  
Inventory Days Days52135 38.5%  
Debtors Days Days4146 87.5%  
Net fixed assets Rs m1,2404,871 25.5%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m7,1673,496 205.0%   
Net worth Rs m7,3333,619 202.6%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m9,9127,509 132.0%  
Interest coverage xNM0.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.5 224.6%   
Return on assets %9.50.6 1,500.8%  
Return on equity %12.8-8.5 -151.0%  
Return on capital %20.81.6 1,311.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m1,0150-   
Fx outflow Rs m3,043517 589.1%   
Net fx Rs m-2,028-517 392.6%   
CASH FLOW
From Operations Rs m537514 104.3%  
From Investments Rs m-476-123 386.9%  
From Financial Activity Rs m-220-387 56.8%  
Net Cashflow Rs m-1604 -3,797.6%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.2 10,111.1%  
FIIs % 1.0 0.6 172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 66.4 43.8%  
Shareholders   28,591 20,121 142.1%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   WYETH LTD  CIPLA  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Nov 16, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - ALEMBIC PHARMA COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS